Bayer CropScience Q1 FY27 PAT up 15% on divestment gain, revenue dips 4%
BAYERCROP · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.0 pts less than Nifty Smallcap 250 and 1.2 pts less than its Pesticides & Agrochemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Bayer CropScience Q1 FY27 (quarter ended June 30, 2026): Revenue from Operations at 1,835 crore versus 1,915 crore YoY (down 4.2 percent). Profit after tax rose to 321.6 crore from 278.7 crore YoY (up 15.4 percent), boosted by a 63.9 crore gain on divestment of marketing rights for formulated products shown under Other Income. EPS at 71.56 versus 62.01. PBT at 402.1 crore versus 335.2 crore. Statutory auditors Deloitte Haskins and Sells issued an unqualified limited review report.
Mixed quarter: top line soft YoY, PAT lift driven by one-time divestment gain; underlying core earnings still under pressure.